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INCREASED ALLOGENEIC TRANSPLANT CONDITIONING INTENSITY
WITHOUT GREATER TOXICITY: A THREE DAY INTRAVENOUS BUSUL-
PHAN (BUSILVEX) BASED SCHEDULE WITH PROMISING RESULTS IN
HIGH RISK HAEMATOLOGICAL MALIGNANCY
Richardson, D.S., Hurlock, C., Hill, K., Newman, J., McKeag, N.,
Groves, L., Orchard, K.H. Southampton University Hospitals, Southamp-
ton, Hampshire, United Kingdom
Reduced intensity conditioning schedules containing Fludarabine
and 2 days oral Busulphan are reported as well tolerated. Published
results and our experience indicates that relapse rates, particularly
for patients with high risk disease, remain unacceptably high. We
have investigated a transplant conditioning schedule containing 3
days Busulphan in combination with Fludarabine and Alemtuzumab,
in patients with advanced disease.We elected to use intravenous Bu-
sulphan (Busilvex) in view of its excellent pharmacokinetic profile.
Methods: 33 patients with haematological malignancy underwent
allogeneic transplantation using a Busilvex-based schedule: 13 re-
ceived 2 days Busilvex (FB2C) and 20 received 3 days (FB3C). The
20 patients who received FB3C were judged to have high-risk dis-
ease. The median age for patients receiving FB2C was 50 years
(range, 21–57) and FB3C 52.5 years (range, 23–64), with a median
follow-up (survivors) of 14.6 months (range 1.6–47.8). Matched sib-
ling/related donors were used for 19 (FB2C-9, FB3C-10) and unre-
lated donors for 14 patients (FB2C-4, FB3C-10). All patients
received in vivo T-cell depletion with Alemtuzumab.
Results: the non-relapse mortality at day 100 and 6 months was
0% and 0% respectively for all patients. Of the patients treated
with FB2C, 8 of 13 (61%) remain alive, all in complete remission
(CR). Of these 3 have relapsed and have responded to further treat-
ment including a second allograft in 2 cases. 5 FB2C patients have
died: 2 relapse, 1 graft versus host disease (GvHD) and 2 frommulti-
organ failure. 17 of 20 (85%) patients who received FB3C are cur-
rently alive. Of the 14 survivors evaluable for response, 12 are in
CR and two are currently being treated for relapse. One patient
with AML has been salvaged from relapse and is currently in CR.
3 FB3C patients have died, all from relapse (all had disease present
at transplant). Both FB2C and FB3C schedules were well tolerated
with no unexpected complications. 1 patient (FB3C) developed
veno-occlusive disease and was successfully treated. Two of 33 pa-
tients (FB2C-1, BF3C-1) experienced grade 3–4 acute GvHD.
Conclusion: a 3 day schedule of intravenous Busulphan in combi-
nation with Fludarabine and Alemtuzumab can be delivered with ex-
cellent tolerability, even to heavily pre-treated and older patients and
shows promising results in the treatment of high risk haematological
malignancy.304
OUTCOMES OF A SECOND REDUCED-INTENSITY UNRELATED CORD
BLOOD TRANSPLANTATION FOLLOWING GRAFT FAILURE
Masuoka, K., Ishiwata, K., Takagi, S., Tsuji, M., Yamamoto, H.,
Matsuno, N., Uchida, N., Wake, A., Taniguchi, S. Toranomon Hospital,
Minato-ku, Tokyo, Japan
Objective:Graft failure represents a serious complication after al-
logeneic stem cell transplantation (allo-SCT). Some recent reports
have demonstrated successful engraftment using unrelated cord
blood (UCB) following graft failure. We therefore analyzed retro-
spectively the results of 321 adult patients with hematologic disorder
who had received allo-SCT between January 2003 and December
2007 at Toranomon Hospital, Tokyo, Japan.
Patients and methods: Twenty of these patients developed graft
failure, and seventeen patients underwent a second reduced-intensity
cord blood transplantation (RI-UCBT) 27 – 62 days (median; 36) af-
ter the first transplant. Diagnoses include de novo AML (n 5 5),
MDS (n 5 4), SAA (n 5 3), ALL(n 5 2), ML(n 5 2), CML (n 5
1). Disease status consisted of advanced (n 5 13) and standard
(n 5 4). HLA disparities were 4/6 match (n 5 2), 5/6 (n 5 3), and
6/6 (n 5 12), and all patients received a single cord blood unit.
TNC/CD34 cell dose were 2.2107/kg (1.7–3.6) and 0.7105/kg
(0.3–1.8), respectively. Conditioning regimen consisted of Fludara-
bine and Alkylating agent. GvHD prophylaxis consisted of tacroli-
mus (Tac) alone in 10, Tac plus mycophenolate mofetil in 5, and
cyclosporine alone in 2.Results: Seven patients died by day 28, the remaining ten patients
were engrafted with complete donor chimerism (median day; 16).
Acute GVHD developed in 6, and chronic GVHD in 4 of the 10 en-
grafted patients. Estimated 1-year disease free survival (DFS) was
38%, and transplantation related mortality (TRM) at 1-year was
50%. In univariate analysis, variables associated with worsened sur-
vival were organ toxicities grade 3 or more (CTCAE ver 3.0) (P 5
0.02) and documented infection at RI-UCBT (p5 0.02), while other
factors were not significant.
Conclusion: Although the other reports of second allo-SCT had
so far been made into the poor survival, our transplantation result
was comparatively good. We conclude that RI-UCBT is a viable
therapeutic option for patients who developed graft failure following
allo-SCT. However, higher TRM was the biggest problem to be
solved to increase the feasibility of this approach.305
ALLOTRANSPLANTS USING ABLATIVE NON-RADIATION BASED REDUCED
TOXICITY CONDITIONING REGIMEN WITH INTRAVENOUS BUSULFAN
PLUS PENTOSTATIN FOR PATIENTS WITH ADVANCED HEMATOLOGIC
MALIGNANCIES
Gerds, A.T., Rodriguez, T.E., Parthasarathy, M., Smith, S.E.,
Vesole, D.H., Stiff, P.J. Loyola University Medical Center, Maywood, IL
Introduction: Stem cell transplantation in the older age group is
the fastest growing indication for allogeneic transplant. In 2007, over
35% of NMDP transplants were for patients.50 largely due to the
increasing application of non-myeloablative regimens. In patients
.60with high risk AML /MDS the leukemia-free survival is approx-
imately 20% after allotransplant. The limited efficacy in this setting
is a result of relapse due to an insufficient anti-AML preparative reg-
imen and/or an inadequate GVL effect in high risk disease. Thus,
there is a need for an ablative yet minimal toxic preparative regimen
(RT-SCT) which results in disease control to allow time for a GVL
response. We have designed an RT-SCT using the conditioning
regimen of intravenous busulfan and pentostatin (Bu/Pent).
Methods: Eligibility included: high risk AML/MDS, age\ 71
and a fully-matched related (MRD) or unrelated donor (MUD).
The conditioning regimen utilized intravenous Bu 1.6 mg/kg every
12 hours on days -7 to -4, and Pent 4 mg/m2 on day -3 and -2 .
GVHD prophylaxis included methotrexate 10 mg/m2on days 1,3,
& 6, and tacrolimus 0.03mg/kg starting day -2 to 160, tapered
over 1 month depending on chimerism status. The primary endpoint
is engraftment (ANC .500/ml x 3 days). Secondary endpoints in-
cludes platelet engraftment, severity of GVHD and regimen related
toxicity.
Results: Eighteen patients have been enrolled: M/F 8/10;
MRD / MUD 10/8. The median age was 65, with 72% patients
.60. Patients were treated for AML (36%), MDS (36%), or
NHL/CLL/ALL (22%) and 78% high risk disease types (as defined
by CIBMTR). Two patients had prior autologous transplants. All
patients engrafted. Survival at 100 day and 1 year were 89% and
49% respectively. The transplant-related mortality was 11% at 100
days and 51% at 1 year. Causes of death included: sepsis (5) and
cGVHD (1). In addition, there were 3 deaths from relapse and one
from unrelated trauma. Non-hematologic toxicities included one
case of VOD. There was no incidence of grade III or greater muco-
sitis or other significant regimen related toxicities. At a median
follow up of 11 months, the relapse rate was 11% in this high risk
population.
Results
Days Days
to
ANC.500
to plt
engraftment
# Plt
transfused
# RBC
transfused
Length of
StayMedian 13 15 5 4 22
Range 11–18 10–38 1–15 0–12 20–29Conclusion: This ongoing study demonstrates the efficacy and
safety of Bu/Pent as a conditioning regimen for RT-SCT. It also
provides an exciting opportunity to extend the application of alloge-
neic transplant to an older population with high risk disease.
